Literature DB >> 9043771

Fludarabine phosphate in lymphoma: an important new therapeutic agent.

P McLaughlin1, L E Robertson, M J Keating.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9043771     DOI： 10.1007/978-1-4615-4129-5_1

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


× No keyword cloud information.
  2 in total

1.  Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.

Authors:  Priyanka Banerjee; Ronghua Zhang; Cristina Ivan; Giovanni Galletti; Karen Clise-Dwyer; Federica Barbaglio; Lydia Scarfò; Miguel Aracil; Christian Klein; William Wierda; William Plunkett; Federico Caligaris-Cappio; Varsha Gandhi; Michael J Keating; Maria Teresa S Bertilaccio
Journal:  Cancer Immunol Res       Date:  2019-09-17       Impact factor: 11.151

2.  High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.

Authors:  Loretta J Nastoupil; Peter McLaughlin; Lei Feng; Sattva S Neelapu; Felipe Samaniego; Fredrick B Hagemeister; Ana Ayala; Jorge E Romaguera; Andre H Goy; Eleanor Neal; Michael Wang; Luis Fayad; Michelle A Fanale; Yasuhiro Oki; Jason R Westin; Maria A Rodriguez; Fernando Cabanillas; Nathan H Fowler
Journal:  Br J Haematol       Date:  2017-03-24       Impact factor: 6.998
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.